CYTOO Launches CYTOOplates™, the Breakthrough Cell Normalization Technology for High Content Screening
Read time:
CYTOO Cell Architects, a developer and marketer of enabling technologies and products for High Content cell Analysis (HCA), has announced the commercial release of CYTOOplates™ 96.
CYTOOplates are developed for pharma, biotech and academic screening center customers employing high content cell-based assays for research, drug safety, and drug screening applications. By restoring spatial information through the exquisite control of cell adhesions, CYTOO’s adhesive micropattern technology normalizes cell phenotypes.
Cell-to-cell variability is reduced and fewer cells are required to detect significant differences between conditions. The ability to decipher a protein re-distribution upon a drug treatment that was previously undetectable in conventional cell culture conditions, while obtaining results by analyzing only 12 to 20 cells compared to the hundreds or thousands usually needed was reported in a study earlier this year by an Institut Curie team.
“Launching the high throughput format of our adhesive micropattern technology is a strategic step forward for CYTOO to reach our industrial markets in drug discovery and toxicology,” said Dr. Alexandra Fuchs, founder and COO. “Our current palette in the CYTOOplate format covers over 100 references to fit most cell lines and applications. Our custom services are also available for technology evaluation and new assay development which puts us in position to address the needs of all our High Content Screening customers.”
CYTOOplates are glass bottom, black frame microplates presenting thousands of adhesive micropatterns per well, compatible with existing HCS equipment and automated microscopes. The range will be extended to include the 384-well format. CYTOOplates complement CYTOO’s initial CYTOOchips™ offer of adhesive micropattern technology in a glass coverslip format. CYTOOchips have already been adopted by hundreds of researchers in private laboratories.
CYTOOplates are developed for pharma, biotech and academic screening center customers employing high content cell-based assays for research, drug safety, and drug screening applications. By restoring spatial information through the exquisite control of cell adhesions, CYTOO’s adhesive micropattern technology normalizes cell phenotypes.
Cell-to-cell variability is reduced and fewer cells are required to detect significant differences between conditions. The ability to decipher a protein re-distribution upon a drug treatment that was previously undetectable in conventional cell culture conditions, while obtaining results by analyzing only 12 to 20 cells compared to the hundreds or thousands usually needed was reported in a study earlier this year by an Institut Curie team.
“Launching the high throughput format of our adhesive micropattern technology is a strategic step forward for CYTOO to reach our industrial markets in drug discovery and toxicology,” said Dr. Alexandra Fuchs, founder and COO. “Our current palette in the CYTOOplate format covers over 100 references to fit most cell lines and applications. Our custom services are also available for technology evaluation and new assay development which puts us in position to address the needs of all our High Content Screening customers.”
CYTOOplates are glass bottom, black frame microplates presenting thousands of adhesive micropatterns per well, compatible with existing HCS equipment and automated microscopes. The range will be extended to include the 384-well format. CYTOOplates complement CYTOO’s initial CYTOOchips™ offer of adhesive micropattern technology in a glass coverslip format. CYTOOchips have already been adopted by hundreds of researchers in private laboratories.
Advertisement
